Research programme: long-acting glucagon-like peptide-1 stimulant - OctoPlus

Drug Profile

Research programme: long-acting glucagon-like peptide-1 stimulant - OctoPlus

Alternative Names: GLP-1 stimulant - OctoPlus; OP-286; OP-286 CR

Latest Information Update: 13 Nov 2012

Price : $50

At a glance

  • Originator Theratechnologies
  • Developer OctoPlus
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 13 Nov 2012 No development reported - Preclinical for Type-2 diabetes mellitus in Netherlands (Parenteral)
  • 22 Sep 2010 Research programme: long-acting glucagon-like peptide-1 agonists - OctoPlus is still available for licensing.
  • 26 Sep 2007 Preclinical trials in Type-2 diabetes mellitus in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top